185040-35-1

Basic information

• Product Name: 4-(ethylaMino)-2-(Methylthio)pyriMidine-5-carbaldehyde
• Synonyms: 4-(ethylaMino)-2-(Methylthio)pyriMidine-5-carbaldehyde;4-(ethylamino)-2-(methylthio)-5-Pyrimidinecarboxaldehyde;4-Ethylamino-2-methanethiopyrimidine-5-carboxaldehyde
• CAS NO: 185040-35-1
• Molecular Formula: C₈H₁₁N₃OS
• Molecular Weight: 197.25744
• EINECS: -0
• Mol File: 185040-35-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 58-61 °C
• Boiling Point: 384.1±27.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• PKA: 3.07±0.10(Predicted)
• CAS DataBase Reference: 4-(ethylaMino)-2-(Methylthio)pyriMidine-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(ethylaMino)-2-(Methylthio)pyriMidine-5-carbaldehyde(185040-35-1)
• EPA Substance Registry System: 4-(ethylaMino)-2-(Methylthio)pyriMidine-5-carbaldehyde(185040-35-1)

Safety Data

• Hazardous Substances Data: 185040-35-1(Hazardous Substances Data)

Usage

General Description

4-(ethylamino)-2-(methylthio)pyrimidine-5-carbaldehyde is a chemical compound with the molecular formula C9H11N3O2S. It is a pyrimidine derivative that contains an aldehyde group and is used in the synthesis of various pharmaceuticals and organic compounds. It has potential applications in medicinal chemistry and drug development due to its ability to interact with biological systems and exhibit pharmacological activity. The compound's structure and properties make it suitable for further research and exploration in the field of organic chemistry.

Upstream product

• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 75-04-7 ethylamine 
• 185040-33-9 4-ethylamino-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester 
• 185040-34-0 (4-ethylamino-2-methanesulfanyl-pyrimidin-5-yl)-methanol 

Downstream Products

• 211244-82-5 8-ethyl-2-(methylsulfanyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 211245-16-8 8-ethyl-2-(4-hydroxyphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one 
• 211245-12-4 8-ethyl-2-(4-methoxyphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one 
• 211245-14-6 8-Ethyl-2-[4-(4-methylpiperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]-pyrimidin-7-one 
• 251371-78-5 {5-[(3,5-Dimethoxy-phenylamino)-methyl]-2-methylsulfanyl-pyrimidin-4-yl}-ethyl-amine 

Relevant articles and documents

Chemically Diverse Group i p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window

p21-activated kinase 1 (PAK1) has an important role in transducing signals in several oncogenic pathways. The concept of inhibiting this kinase has garnered significant interest over the past decade, particularly for targeting cancers associated with PAK1 amplification. Animal studies with the selective group I PAK (pan-PAK1, 2, 3) inhibitor G-5555 from the pyrido[2,3-d]pyrimidin-7-one class uncovered acute toxicity with a narrow therapeutic window. To attempt mitigating the toxicity, we introduced significant structural changes, culminating in the discovery of the potent pyridone side chain analogue G-9791. Mouse tolerability studies with this compound, other members of this series, and compounds from two structurally distinct classes revealed persistent toxicity and a correlation of minimum toxic concentrations and PAK1/2 mediated cellular potencies. Broad screening of selected PAK inhibitors revealed PAK1, 2, and 3 as the only overlapping targets. Our data suggest acute cardiovascular toxicity resulting from the inhibition of PAK2, which may be enhanced by PAK1 inhibition, and cautions against continued pursuit of pan-group I PAK inhibitors in drug discovery.

PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS

This disclosure relates to compounds, methods for their preparation, pharmaceutical compositions including these compounds and methods for the treatment of cellular proliferative disorders, including, but not limited to, cancer.

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.